^
    Back
    Association details:
    Biomarker:MET mutation
    Cancer:Renal Cell Carcinoma
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor) +
    Orpathys (savolitinib) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO)

    Published date:
    02/21/2023
    Excerpt:
    The combination of savolitinib and durvalumab was tolerable and associated with high cRRs in the exploratory MET-driven subset.
    DOI:
    10.1200/JCO.22.01414
    Trial ID:
    CALYPSO